Retatrutide calculators

This hub gathers the four Retatrutide calculators in one place — reconstitution, dose, mg ↔ units, and vial duration — pre-filled with a 10 mg / 2 mL example so the math is concrete the moment the page loads. Retatrutide sits in the GLP-1 category, and the numbers each tool surfaces are tuned to how people actually log this peptide: one shot a week at the 2 mg example dose. A triple agonist (GIP / GLP-1 / glucagon) currently studied in clinical trials. Tracked weekly in most logs.

At the example concentration of 5 mg/mL, a 2 mg Retatrutide dose draws roughly 40 units on a U-100 insulin syringe — the Dose calculator on the hub shows that working in real time, and the mg ↔ units converter flips it back the other way for people who think in milligrams. The Reconstitution calculator answers the day-one question (how much bacteriostatic water to add and what concentration that gives), and the Vial Duration calculator answers the planning question (how many weeks one vial covers).

For this 10 mg Retatrutide vial, the example numbers imply about 5 doses per vial and roughly 5 weeks of coverage at 1 dose per week — that's the math the Vial Duration tool exposes, and it's the number most people use to decide when to reorder. Every calculator on the hub uses these same five inputs (vial mg, diluent mL, dose, doses-per-week, syringe type), so changing your real numbers in one tool gives consistent answers across the others.

Once-weekly subcutaneous injection is the default cadence in most retatrutide logs. Each draw is small enough that a U-100 insulin syringe is the standard tool — the volumes involved are too small to read accurately on a tuberculin syringe.

Because retatrutide is potent at small milligram counts, dose escalation tends to be gradual and well-tracked. The exact week and unit count of each step is the kind of information that is hard to reconstruct from memory months later, which is why a structured dose log is more durable than scattered notes.

Dosing schedules documented in published Phase 2 clinical trials for retatrutide have involved a notably steep titration. Study protocols have detailed starting doses that escalate at predetermined intervals to much higher terminal doses than those typical for related peptides. For example, a documented titration schedule involved monthly escalations from a starting dose, progressing through tiers such as 2 mg, 4 mg, 8 mg, and up to a 12 mg maximum dose, all administered on a weekly cadence. For personal tracking, these published trial schedules are the only available structural reference points for logging dose escalation over a period of months.